Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Broad betacoronavirus neutralization by a stem helix-specific human antibody.

Tytuł:
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Autorzy:
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sauer MM; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Low JS; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Housley MP; Vir Biotechnology, San Francisco, CA 94158, USA.
Noack J; Vir Biotechnology, San Francisco, CA 94158, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA.
Jerak J; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA.
Islam S; Vir Biotechnology, San Francisco, CA 94158, USA.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Foo C; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Coelmont L; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cassotta A; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Ceschi A; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Cippà PE; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Faculty of Medicine, University of Zurich, 8057 Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Ceruti S; Intensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Riva A; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.
Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Smithey M; Vir Biotechnology, San Francisco, CA 94158, USA.
Hong D; Vir Biotechnology, San Francisco, CA 94158, USA.
Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA.
Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium.
Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; UT Southwestern Medical Center, Dallas, TX 75390, USA.; Washington University School of Medicine, St. Louis, MO 63110, USA.
Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Źródło:
Science (New York, N.Y.) [Science] 2021 Sep 03; Vol. 373 (6559), pp. 1109-1116. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: : Washington, DC : American Association for the Advancement of Science
Original Publication: New York, N.Y. : [s.n.] 1880-
MeSH Terms:
Virus Internalization*
Antibodies, Monoclonal/*immunology
Antibodies, Neutralizing/*immunology
Betacoronavirus/*immunology
Spike Glycoprotein, Coronavirus/*chemistry
Spike Glycoprotein, Coronavirus/*immunology
Viral Vaccines/*immunology
Animals ; Antibodies, Monoclonal/isolation & purification ; Antibodies, Neutralizing/isolation & purification ; Convalescence ; Cricetinae ; Cross Reactions ; Humans ; Immunoglobulin Fab Fragments/immunology ; Immunoglobulin Fc Fragments/immunology ; Jurkat Cells ; Lung/immunology ; Membrane Fusion/immunology ; Neutralization Tests ; Peptide Mapping ; Protein Conformation, alpha-Helical ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Viral Load/immunology
References:
Elife. 2020 Oct 28;9:. (PMID: 33112236)
Science. 2021 Aug 6;373(6555):648-654. (PMID: 34210893)
J Comput Chem. 2004 Oct;25(13):1605-12. (PMID: 15264254)
Nat Struct Mol Biol. 2019 Jun;26(6):481-489. (PMID: 31160783)
Bioinformatics. 2018 Mar 1;34(5):867-868. (PMID: 29096012)
Nat Commun. 2021 Mar 17;12(1):1715. (PMID: 33731724)
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5. (PMID: 32735849)
Fly (Austin). 2012 Apr-Jun;6(2):80-92. (PMID: 22728672)
Nature. 2021 Apr;592(7855):623-628. (PMID: 33762730)
Nature. 2013 Jul 4;499(7456):102-6. (PMID: 23698367)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Nat Struct Mol Biol. 2019 Dec;26(12):1151-1157. (PMID: 31792450)
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67. (PMID: 21460454)
Cell. 2020 Nov 25;183(5):1367-1382.e17. (PMID: 33160446)
Cell Res. 2017 Jan;27(1):119-129. (PMID: 28008928)
Nature. 2020 Jul;583(7815):290-295. (PMID: 32422645)
Mol Cell. 2020 May 21;78(4):779-784.e5. (PMID: 32362314)
Sci Transl Med. 2019 Oct 30;11(516):. (PMID: 31666399)
Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473)
Cell. 2021 Apr 1;184(7):1804-1820.e16. (PMID: 33691139)
Nat Med. 2018 May;24(4):401-407. (PMID: 29554084)
Cell. 2016 Jul 28;166(3):596-608. (PMID: 27453466)
J Virol. 1993 Mar;67(3):1185-94. (PMID: 7679743)
Science. 2011 Oct 21;334(6054):373-6. (PMID: 22021856)
J Virol. 2015 Sep;89(17):9119-23. (PMID: 26063432)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Microbiol Spectr. 2016 Dec;4(6):. (PMID: 28087938)
Nature. 2014 Mar 13;507(7491):201-6. (PMID: 24499818)
PLoS Comput Biol. 2020 Jul 10;16(7):e1007731. (PMID: 32649725)
IUCrJ. 2019 Jan 01;6(Pt 1):5-17. (PMID: 30713699)
Cell. 2019 Mar 7;176(6):1420-1431.e17. (PMID: 30849373)
Nat Med. 2014 Feb;20(2):143-51. (PMID: 24412922)
J Virol. 2004 Jul;78(13):6938-45. (PMID: 15194770)
PLoS One. 2012;7(11):e50366. (PMID: 23185609)
Gigascience. 2021 Feb 16;10(2):. (PMID: 33590861)
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4. (PMID: 33535027)
Science. 2020 Sep 25;369(6511):1586-1592. (PMID: 32694201)
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162. (PMID: 29073020)
Nature. 2016 Mar 3;531(7592):114-117. (PMID: 26855426)
Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448)
Science. 2011 Aug 12;333(6044):850-6. (PMID: 21798894)
Ultramicroscopy. 2013 Dec;135:24-35. (PMID: 23872039)
Bioinformatics. 2016 Oct 1;32(19):3047-8. (PMID: 27312411)
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002)
Nature. 2020 Dec;588(7838):485-490. (PMID: 33032297)
Adv Virus Res. 2019;105:93-116. (PMID: 31522710)
Cell. 2021 Mar 4;184(5):1171-1187.e20. (PMID: 33621484)
Science. 2020 Nov 20;370(6519):950-957. (PMID: 32972994)
Nat Immunol. 2019 Mar;20(3):362-372. (PMID: 30742080)
Nat Struct Mol Biol. 2021 Jun;28(6):478-486. (PMID: 33981021)
J Exp Med. 2021 Mar 1;218(3):. (PMID: 33211088)
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877. (PMID: 31588918)
J Clin Invest. 2010 May;120(5):1663-73. (PMID: 20389023)
Nat Biotechnol. 2017 Apr 11;35(4):316-319. (PMID: 28398311)
Nat Commun. 2020 Nov 17;11(1):5838. (PMID: 33203860)
Nat Methods. 2018 Jul;15(7):475-476. (PMID: 29967506)
Nucleic Acids Res. 2012 Dec;40(22):11189-201. (PMID: 23066108)
Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):519-530. (PMID: 29872003)
Eur J Immunol. 2009 May;39(5):1260-70. (PMID: 19404981)
EBioMedicine. 2021 Jun;68:103403. (PMID: 34049240)
Nat Commun. 2017 Apr 10;8:15092. (PMID: 28393837)
Science. 2020 Jul 17;369(6501):330-333. (PMID: 32366695)
J Struct Biol. 2005 Jul;151(1):41-60. (PMID: 15890530)
J Virol. 2010 Apr;84(7):3210-9. (PMID: 20071581)
Nature. 2020 Sep;585(7826):588-590. (PMID: 32698190)
Science. 2020 May 15;368(6492):. (PMID: 32409444)
Nat Commun. 2020 Jul 17;11(1):3618. (PMID: 32681106)
Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844)
Nat Methods. 2019 Nov;16(11):1146-1152. (PMID: 31591575)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Nat Commun. 2020 Jun 1;11(1):2806. (PMID: 32483236)
N Engl J Med. 2020 Dec 3;383(23):2291-2293. (PMID: 33176080)
Euro Surveill. 2020 Jul;25(28):. (PMID: 32700671)
Nat Commun. 2021 May 19;12(1):2938. (PMID: 34011939)
Cell. 2019 Feb 21;176(5):1026-1039.e15. (PMID: 30712865)
Sci Rep. 2018 Oct 24;8(1):15701. (PMID: 30356097)
Science. 2021 Mar 12;371(6534):1139-1142. (PMID: 33536258)
Cell. 2021 Apr 29;184(9):2332-2347.e16. (PMID: 33761326)
Grant Information:
DP1 AI158186 United States AI NIAID NIH HHS; S10 OD023476 United States OD NIH HHS; P30 GM133894 United States GM NIGMS NIH HHS; HHSN272201700059C United States AI NIAID NIH HHS; U01 AI151698 United States AI NIAID NIH HHS
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Antibodies, Neutralizing)
0 (Immunoglobulin Fab Fragments)
0 (Immunoglobulin Fc Fragments)
0 (Spike Glycoprotein, Coronavirus)
0 (Viral Vaccines)
Entry Date(s):
Date Created: 20210804 Date Completed: 20211001 Latest Revision: 20240214
Update Code:
20240214
PubMed Central ID:
PMC9268357
DOI:
10.1126/science.abj3321
PMID:
34344823
Czasopismo naukowe
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus countermeasures. We describe five monoclonal antibodies (mAbs) cross-reacting with the stem helix of multiple betacoronavirus spike glycoproteins isolated from COVID-19 convalescent individuals. Using structural and functional studies, we show that the mAb with the greatest breadth (S2P6) neutralizes pseudotyped viruses from three different subgenera through the inhibition of membrane fusion, and we delineate the molecular basis for its cross-reactivity. S2P6 reduces viral burden in hamsters challenged with SARS-CoV-2 through viral neutralization and Fc-mediated effector functions. Stem helix antibodies are rare, oftentimes of narrow specificity, and can acquire neutralization breadth through somatic mutations. These data provide a framework for structure-guided design of pan-betacoronavirus vaccines eliciting broad protection.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies